We provide confidence to patients, oncologists, and pharmaceutical companies in their life-changing cancer therapy decisions.
Meet our executive team
Chief Executive Officer
Eric is a highly accomplished and passionate leader with 30 years of experience in medical sales and marketing with a particular focus on diagnostics. As Chief Executive Officer of Kiyatec Inc., he demonstrates exceptional leadership in the functional oncology space, overseeing sales, marketing, and operations. Eric has a proven track record of success, evident in his ability to secure fundraising for ongoing initiatives, rebrand products for patient-focused launches, and strategically restructure organizations for optimal performance.
In his previous roles, including Senior Vice President at LumiraDx and Chief Commercial Officer/GM at Lumos Diagnostics, Eric showcased his expertise in expanding market share, establishing international distribution networks, and driving significant revenue growth. His work at Astute Medical, Singulex, and Biosite Corporation further highlights his ability to lead successful product launches, secure funding rounds, and achieve remarkable growth in the highly competitive medical diagnostics industry.
Eric’s strategic foresight, fundraising prowess, and unwavering commitment to bringing potentially lifesaving diagnostics to market make him a driving force in advancing healthcare innovation and improving patient outcomes.
Tessa DesRochers, PhD
Chief Scientific Officer, Vice President of Preclinical Services
Dr. Tessa DesRochers is responsible for managing all research and development within Kiyatec, including all government contracts and grants, external collaborations, and internal preclinical and clinical assay development. Before joining the company, Tessa was in the Department of Biomedical Engineering at Tufts University where she developed bioengineered 3D models of human kidney tissue and breast cancer with applications in the areas of nephrotoxicology, disease modeling, and infectious disease. She has published numerous peer-reviewed articles in the area of tissue engineering and disease applications, has presented a number of abstracts at multiple scientific meetings, and serves as an ad hoc reviewer for several peer-reviewed journals.
As a “military brat,” Tessa grew up in numerous locations, including California, England, and Ohio, before her family settled in New Hampshire. She attended the University of New Hampshire where she graduated cum laude with a BS in biochemistry. She received her PhD from Tufts University’s Sackler School of Graduate Biomedical Sciences in cell, molecular, and developmental biology where her thesis focused upon epigenetic gene regulation in a 3D model of human skin. Her postdoctoral training included a year at Children’s Hospital in Boston and subsequent training in the lab of Dr. David Kaplan at Tufts University. Tessa is committed to the development of 3D tissues as better models of human development and disease.
Melissa Rayner, MS, MB(ASCP)CM
Vice President of Operations
As Vice President of Operations for Kiyatec, Melissa Rayner oversees laboratory and facility operations as well as market access and reimbursement. With an impressive career spanning nearly 30 years, Melissa brings extensive expertise in research, including 19 years focused on plant genetics, molecular genetics, and human genetics along with 9 years of oncology laboratory management experience. She is also a contributing author for numerous peer-reviewed articles in the fields of hereditary diseases and oncology.
In her previous roles, including Director of Laboratory Operations at Selah Genomics and the John P. Hussman Institute for Human Genomics, Melissa has demonstrated a remarkable track record. Her accomplishments include obtaining CLIA, CAP, and state laboratory certifications, managing facility relocations and renovations, and ensuring successful medical billing for clinical assays.
A proud graduate of the North Carolina School of Science and Mathematics, Melissa also graduated magna cum laude with a BS in biology from North Carolina Central University and received her MS in biotechnology regulatory affairs at the University of Maryland Global Campus. Since 2014, she has held certifications as a technologist in molecular biology from the American Society for Clinical Pathology and a molecular pathology technologist license from the State of Florida Division of Medical Quality Assurance. Melissa’s commitment to excellence and her extensive experience make her a valuable asset to the Kiyatec team.
National Sales Director
Scott Isacksen is an accomplished strategist and sales leader with three decades of experience in effective business development, growth, and team leadership. In his current role as National Sales Director, Scott is leveraging his business acumen and knack for building and empowering high-performing teams to solidify Kiyatec’s reputation as a leader in functional precision oncology. And with his talent for shaping comprehensive commercial infrastructures, he’s perfectly positioned to shepherd Kiyatec toward a future of lasting success.
Throughout his career, Scott has consistently identified new business opportunities, devised market strategies, and cultivated enduring stakeholder relationships. In his most recent role as Senior Sales Director at Myovant Sciences, he played a crucial role in building the initial sales team and launching a novel prostate cancer treatment. Scott’s wealth of experience in launching and growing startups, along with his successful track record of bringing over 20 products to market, has firmly established him as an influential and dynamic leader. With his deep understanding of the pharmaceutical, biotech, and diagnostic landscape, he continues to make a significant impact by driving innovation, accelerating growth, and reshaping the trajectory of the organizations he collaborates with.
Meet our Board of Directors
Mr. Robart is an experienced healthcare executive with a solid foundation in near- and long-term strategic planning, development, and execution. He is the cofounder and managing partner of Seae Ventures, a healthcare venture fund with a particular focus on women and minority entrepreneurs. Prior to founding Seae in 2019, Jason held a number of executive roles at Blue Cross Blue Shield of Massachusetts, including chief strategy officer, president and CEO of Zaffre Investments, (BCBSMA’s corporate venture arm), chief human resources officer and SVP of organizational effectiveness, and segment leader for national accounts. Previous positions also include executive vice president for Health Dialog, an international healthcare analytics company, and principal at Mercer Human Resource Consulting. Jason holds a BS in political science from Middlebury College and a Certificate in Private Equity and Venture Capital from Harvard Business School.
Matthew R. Gevaert, PhD
Dr. Matthew (Matt) Gevaert is a cofounder and board member of Kiyatec, Inc. Kiyatec is disrupting cancer therapy selection with patient-specific prediction of response to drug therapies, prior to treatment. To date, Kiyatec has been awarded more than $5 million of competitively awarded federal funding, including contracts from the National Cancer Institute, cultivated clinical collaborations at leading national cancer institutions, and built productive relationships with premier biopharmaceutical companies developing the cancer therapies of the future.
Matt is a graduate of the University of Waterloo (BS, chemistry) and of Clemson University MS and PhD, bioengineering). He serves on a number of professional and community boards and occasionally teaches an MBA graduate course in technology entrepreneurship for professional business students.
Robert Silverman, MBA
Mr. Silverman is the former CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer. He was instrumental in growing this company into a global, fully integrated business, with a strong foundation of significant clinical utility and commercial momentum. Robert successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of $270 million and then facilitated the integration of mtm into Roche.
Prior to mtm laboratories, Robert was the senior vice president of worldwide commercial operations for ViaCell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytyc Corporation. During his tenure at Cytyc, he served as the vice president of marketing and the vice president of international and was integral in launching and establishing the core technology (the ThinPrep Pap Test) into the standard of care for cervical cancer screening. Previous positions include vice president of marketing for Pasteur Merieux Connaught, director of new product development for Abbott Laboratories Pharmaceutical Products Division, and management consultant with Bain and Company.
Robert earned his MS in marketing and finance from Northwestern’s Kellogg Graduate School of Management and received his BS in pharmacy from the University of Michigan. He currently works with several companies in a board and advisory capacity.
Christopher Brotherton, MBA
Mr. Brotherton is the president of Ortec, Inc., a South Carolina company offering custom manufacturing services for pharmaceutical, medical device, and combination products. Prior to joining Ortec, Christopher was with Nalco Company where he held several positions in product marketing, international marketing, and strategic mergers and acquisitions. He holds a BS in chemistry from Clemson University and an MBA from Wake Forest University.
Bruce Nash, MD, MBA
Dr. Nash brings over 30 years of executive-level healthcare experience in the managed care, hospital, and medical group practice settings. Previously Bruce served as chief physician executive and senior vice president at Blue Cross Blue Shield of Massachusetts, one of the nation’s leading health insurance plans. During his career, Bruce has held executive leadership positions in both managed care (Kaiser Permanente, Capital District Physicians’ Health Plan) and healthcare (Northern Berkshire Health System, North Adams Regional Hospital) organizations. He serves on the boards of the Blue Cross Blue Shield Foundation and the Network for Excellence in Health Innovation (NEHI), while also serving on the Board of Strategic Advisors at the Excel Venture Management Fund and the Clinical Advisory Group at the Blue Venture Fund. Bruce is a board-certified physician who completed his residency training at Duke University. He earned his MBA in health sector management from Duke University’s Fuqua School of Business.